Health Care · Medicinal Chemicals & Botanical Products · OTC · CIK 1909747 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $0.42Day +9.21%Mkt cap $76M1Y −27.3%Off 52W high −57.7%Vol (1Y) 134.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,786 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.0% of sh out |
| Days to cover1.0d |
| Next report (est.)2026-10-26 |
Short interest is FINRA semi-monthly, settlement 2026-07-15.
| Sales (TTM)$265.5M |
| Earnings (TTM)-$71.4M |
| Net margin−26.1% |
| Total debt / EBITDA5.74× |
| Sales growth 3Y−2.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−34.1% |
| 1Y−27.3% |
| 3Y−13.5% |
| 5Y−91.6% |
| Since incept. (ann.)−21.4% |
Total return through 2026-07-30 · series begins 2019-06-18. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)134.9% |
| Ann. volatility (3Y)123.6% |
| Sharpe (1Y)0.46 |
| Sharpe (3Y)0.56 |
| Max drawdown (1Y)−59.3% |
| Max drawdown (3Y)−74.4% |
| Beta (3Y vs SPY)−0.57 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
No 13F holders on file for JUSHF.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.10 | — | $66.4M | +4.1% |
| 2025-12-31 | 2026-03-31 | — | — | $68.3M | +3.8% |
| 2025-09-30 | 2025-11-04 | −$0.12 | — | $65.7M | +6.6% |
| 2025-06-30 | 2025-08-05 | −$0.06 | — | $65.0M | +0.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-26 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
Retail Cannabis 90% · Wholesale Cannabis 10%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
